Research & Development
Pfizer, BioNTech to Submit Emergency Use Authorization Request Today to the US FDA for COVID-19 Vaccine
20 November 2020 - - US-based drugmaker Pfizer Inc. (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) have submitted a request to the US Food and Drug Administration for Emergency Use Authorization of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the US by the middle to end of December 2020, the company said.

The submission is based on a vaccine efficacy rate of 95% (p
Login
Username:

Password:


Related Headlines

Applied DNA Expands Addressable Market for Linea COVID-19 Assay Kit via Amendment to FDA EUA

FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection

European Commission's Approves Advance Purchase Agreement for Initial 80m Doses of Moderna mRNA COVID-19 Vaccine

Bristol Myers Squibb Receives European Commission Approval for Opdivo as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Alnylam Launches Value-Based Agreement Framework for Oxlumo to Accelerate Access for Patients

Vedanta Biosciences Names Karuna Therapeutics CFO Ignelzi to Its Board of Directors

US Food and Drug Administration Approves Oxlumo for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients

Moderna declares advance purchase agreement with European Commission for initial 80 million doses of mRNA vaccine against COVID-19

Oramed Pharmaceuticals screens first patients in global Phase three trials of ORMD-0801

Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome Pain Did Not Meet Primary Endpoint

Ender Diagnostics Receives FDA Notification for Rapid and Reliable COVID-19 Tests

Appili Therapeutics Starts New Phase 3 Clinical Trial to Evaluate Avigan Tablets in the Prevention of COVID-19

RapidRona Self-Collection COVID-19 Kit is Awarded an Emergency Use Authorization from the FDA

Genentech reports FDA approval of Xofluza for post-exposure prophylaxis

US FDA approves Alnylam Pharmaceuticals' Oxlumo